Molecular pharmaceuticsAnimalsHumansDoxorubicinBreast NeoplasmsFemale
Boosting Oral Chemotherapy Efficacy and Ameliorating Intestinal Dysbiosis via a Microfluidic-Engineered RGD-Targeted Nanoplatform against Breast Cancer.
Xiaohong Jiang, Yuanyuan Xu, Bin Shen, Yanping Ji, Lili Shi, Jinlai Gao, Jingjian Dong
Published: 202610.1021/acs.molpharmaceut.5c01256
Abstract
Doxorubicin (DOX) faces significant challenges in oral chemotherapy due to low intestinal permeability and extensive first-pass metabolism. We developed microfluidics-prepared RGD-modified solid lipid nanoparticles (MF-SLNs) to enhance oral anticance…
Preview only. Read the full abstract at the source